Ferguson L R
Cancer Research Laboratory, University of Auckland Medical School, Private Bag 92019, Auckland 1000, New Zealand.
Mutat Res. 1998 May 25;400(1-2):271-8. doi: 10.1016/s0027-5107(98)00039-6.
Many inhibitors of topoisomerase II enzymes are potent mutagens, leading to major chromosomal deletions, illegitimate recombination and aneuploidy. There is increasing evidence that they are also human carcinogens. However, their lack of chemical reactivity means that they may give weak or negative results in commonly used mutagenicity tests, or may give data with characteristics quite distinct from chemicals that alkylate DNA. They do not form DNA adducts and assays such as 32P-postlabelling will not detect their presence in the body. They are generally not point mutagens and may fail to provide distinctive fingerprints in mutation spectra. These characteristics may be limiting a realistic evaluation of their role in human carcinogenesis using current methodologies.
许多拓扑异构酶II酶抑制剂是强效诱变剂,可导致主要的染色体缺失、异常重组和非整倍体。越来越多的证据表明它们也是人类致癌物。然而,它们缺乏化学反应性,这意味着它们在常用的致突变性试验中可能给出微弱或阴性结果,或者可能给出与使DNA烷基化的化学物质截然不同的数据特征。它们不会形成DNA加合物,诸如32P后标记等检测方法无法检测到它们在体内的存在。它们通常不是点突变诱变剂,可能无法在突变谱中提供独特的指纹图谱。这些特性可能限制了使用当前方法对它们在人类致癌作用中所起作用进行现实评估。